Replies to post #12485 on Biotech Values

[DewDiligence]

>>do you still have a position in YMI?<<

I never owned YMI, although I do think the company is cheap. I just haven’t had a chance to do the kind of DD it would take to be comfortable with it.

One of my concerns is that the Tesmilifene trial might end up being a Pyrrhic victory for YMI if interest in anthracyclines in first-line metastatic BC should wane due to new data about other chemo drugs. Maybe this ought not to be a major issue, but it bothers me to some extent.

Perhaps more important, YMI strikes me as a very high-DD company. GTCB and DNDN are also high-DD companies, and there are only so many hours in the day. Regards, Dew